To develop evidence-based clinical algorithms for CA-ARTI and assess the diagnostic accuracy and the
clinical utility of POCT for specific groups of patients, clinical findings, and settings.
To develop evidence-based URS’s to support future development and implementation of rapid diagnostics
to reduce AMR for CA-ARTI, and to refine the methods and processes to make them applicable to point of
care diagnostic developments for other infectious disease indications).
To create a technical roadmap that incorporates recommendations for short- and long-term goals to help
companies and research institutions prioritize investment decisions in the field of CA-ARTI-Dx.
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226melanie.hostehttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngmelanie.hoste2020-01-10 14:15:252020-01-10 14:18:20Headway made for Point Prevalence Audit Survey in primary and long-term care settings
https://value-dx.eu/wp-content/uploads/2019/09/VALUE-Dx_logo_white4.png4281226Daniele Pazzolahttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2019-11-21 12:20:002020-01-10 14:18:44IMI article - Technology, not instinct, should guide antibiotic prescribing. A Q&A with Herman Goossens
https://value-dx.eu/wp-content/uploads/2019/10/ERS-web.png238914melanie.hostehttps://value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngmelanie.hoste2019-10-15 14:21:512019-10-15 14:33:51Diagnostics in fighting antimicrobial resistance: A joint session between ESCMID and ERS at the ERS International Congress 2019
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.